KURA ONCOLOGY, INC. Net Cash Provided by (Used in) Investing Activities, Continuing Operations
KURA ONCOLOGY, INC. (KURA) reported Net Cash Provided by (Used in) Investing Activities, Continuing Operations of -$29.71 million for the 3-month period ending 2018-03-31, per its 10-Q filed 2018-05-08.
Discontinued › Cash Flow › Investing Activities
us-gaap:NetCashProvidedByUsedInInvestingActivitiesContinuingOperations · last filed 2018-05-08
- KURA ONCOLOGY, INC. net cash provided by (used in) investing activities, continuing operations for the quarter ending 2018-03-31 was -$29.71M, a 411.66% decline year-over-year.
- KURA ONCOLOGY, INC. net cash provided by (used in) investing activities, continuing operations for the quarter ending 2017-12-31 was -$4.09M, a 142.26% decline year-over-year.
- KURA ONCOLOGY, INC. net cash provided by (used in) investing activities, continuing operations for the quarter ending 2017-09-30 was -$36.29M, a 25480.42% decline year-over-year.
- KURA ONCOLOGY, INC. net cash provided by (used in) investing activities, continuing operations for the quarter ending 2017-06-30 was $7.43M.
- KURA ONCOLOGY, INC. net cash provided by (used in) investing activities, continuing operations for fiscal 2017 was -$23.42M, a 292.30% decline from fiscal 2016.
- KURA ONCOLOGY, INC. net cash provided by (used in) investing activities, continuing operations for fiscal 2016 was $12.18M.
- KURA ONCOLOGY, INC. net cash provided by (used in) investing activities, continuing operations for fiscal 2015 was -$70.63M.
| Period end | Net Cash Provided by (Used in) Investing Activities, Continuing Operations 1 month | Net Cash Provided by (Used in) Investing Activities, Continuing Operations 3 month | Net Cash Provided by (Used in) Investing Activities, Continuing Operations 4 month | Net Cash Provided by (Used in) Investing Activities, Continuing Operations 6 month | Net Cash Provided by (Used in) Investing Activities, Continuing Operations 9 month | Net Cash Provided by (Used in) Investing Activities, Continuing Operations 12 month |
|---|---|---|---|---|---|---|
| 2018-03-31 | -$29.71M 10-Q · filed 2018-05-08 | -$33.80M derived: sum of 2 quarters · filed 2018-05-08 | -$70.10M derived: sum of 3 quarters · filed 2018-05-08 | -$62.67M derived: sum of 4 quarters · filed 2018-05-08 | ||
| 2017-12-31 | -$4.09M derived: 10-K 12 month − 10-Q 9 month · filed 2018-03-12 | -$40.38M derived: sum of 2 quarters · filed 2018-03-12 | -$32.95M derived: sum of 3 quarters · filed 2018-03-12 | -$23.42M 10-K · filed 2018-03-12 | ||
| 2017-09-30 | -$36.29M derived: 10-Q 9 month − 10-Q 6 month · filed 2017-11-07 | -$28.86M derived: sum of 2 quarters · filed 2017-11-07 | -$19.33M 10-Q · filed 2017-11-07 | -$9.65M derived: sum of 4 quarters · filed 2018-05-08 | ||
| 2017-06-30 | $7.43M derived: 10-Q 6 month − 10-Q 3 month · filed 2017-08-07 | $16.97M 10-Q · filed 2017-08-07 | $26.65M derived: sum of 3 quarters · filed 2018-05-08 | $26.79M derived: sum of 4 quarters · filed 2018-05-08 | ||
| 2017-03-31 | $9.53M 10-Q · filed 2018-05-08 | $19.21M derived: sum of 2 quarters · filed 2018-05-08 | $19.36M derived: sum of 3 quarters · filed 2018-05-08 | $13.52M derived: sum of 4 quarters · filed 2018-05-08 | ||
| 2016-12-31 | $9.68M derived: 10-K 12 month − 10-Q 9 month · filed 2018-03-12 | $9.82M derived: sum of 2 quarters · filed 2018-03-12 | $3.98M derived: sum of 3 quarters · filed 2018-03-12 | $12.18M 10-K · filed 2018-03-12 | ||
| 2016-09-30 | $143.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2017-11-07 | -$5.70M derived: sum of 2 quarters · filed 2017-11-07 | $2.50M 10-Q · filed 2017-11-07 | -$37.95M derived: sum of 4 quarters · filed 2017-11-07 | ||
| 2016-06-30 | -$5.84M derived: 10-Q 6 month − 10-Q 3 month · filed 2017-08-07 | $2.35M 10-Q · filed 2017-08-07 | -$38.09M derived: sum of 3 quarters · filed 2017-08-07 | -$41.98M derived: sum of 4 quarters · filed 2017-08-07 | ||
| 2016-03-31 | $8.20M 10-Q · filed 2017-05-15 | -$32.25M derived: sum of 2 quarters · filed 2017-05-15 | -$36.14M derived: sum of 3 quarters · filed 2017-05-15 | -$62.42M derived: sum of 4 quarters · filed 2017-05-15 | ||
| 2015-12-31 | -$40.45M derived: 10-K 12 month − 10-Q 9 month · filed 2017-03-14 | -$44.34M derived: sum of 2 quarters · filed 2017-03-14 | -$70.62M derived: sum of 3 quarters · filed 2017-03-14 | -$70.63M 10-K · filed 2017-03-14 | ||
| 2015-09-30 | -$3.89M derived: 10-Q 9 month − 10-Q 6 month · filed 2016-11-07 | -$30.17M derived: sum of 2 quarters · filed 2016-11-07 | -$30.18M 10-Q · filed 2016-11-07 | |||
| 2015-06-30 | -$26.28M derived: 10-Q 6 month − 10-Q 3 month · filed 2016-08-10 | -$26.29M 10-Q · filed 2016-08-10 | ||||
| 2015-03-31 | -$10.00K 10-Q · filed 2016-05-11 | |||||
| 2014-12-31 | -$28.00K 10-K · filed 2016-03-17 | |||||
| 2014-09-30 | -$11.00K 10-Q · filed 2015-11-13 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Arbutus Biopharma Corp (ABUS) | $0.965B | 6.19 | |
| Corvus Pharmaceuticals, Inc. (CRVS) | United States | $0.994B | -23.25 |
| Jade Biosciences, Inc. (JBIO) | United States | $0.936B | -9.21 |
| Janux Therapeutics, Inc. (JANX) | United States | $1.019B | -9.15 |
| Pacira BioSciences, Inc. (PCRX) | United States | $1.020B | 69.03 |
| MoonLake Immunotherapeutics (MLTX) | Switzerland | $1.031B | -5.43 |
| Apnimed, Inc. (APMD) | United States | $0.899B | |
| RIGEL PHARMACEUTICALS INC (RIGL) | United States | $0.893B | 2.25 |
| Savara Inc (SVRA) | United States | $1.044B | -9.10 |
| Theravance Biopharma, Inc. (TBPH) | $0.885B | 16.40 |